-
Not all states are facing a crisis with their AIDS Drug Assistance Programs (ADAPs) this year, despite the widespread economic downturn.
-
-
Peter Leone, MD, a professor of Medicine at the University of North Carolina in Chapel Hill and the medical director of the North Carolina HIV and STD Prevention and Care Program, has studied the ARCHITECT HIV Combo Assay, a new HIV test that identifies infection sooner than the standard antibody HIV test.
-
Few diseases have anywhere near the clout, exposure, and clinical trial support of HIV/AIDS. Dedicated foundations, advocacy groups, and international organizations have spent more than two decades working to ensure HIV prevention and medication trials are a top priority for governments and private industry.
-
On July 23, 2009, FDA granted approval for zidovudine 60 mg scored tablets for pediatric use, manufactured by Aurobindo Pharma Limited of Hyderabad, India. The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).
-
There are a number of ways that comparative effectiveness research (CER) might impact health care research, practice, and policy, according to a new study.
-
Comparative effectiveness research (CER) grants will be distributed by three federal agencies, including the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health, and the Secretary of Health and Human Services.
-
An alarm went off when the research center at Yale University in New Haven, CT, was approached by a vendor who offered to capture their uncollected research payments for a fee equaling 70% of what they collected.
-
-
Comparative effectiveness research (CER) isn't new, but it's been given a huge boost this year with the stimulus package's approval of $1.1 billion for CER grants, distributed by several government agencies.
